In the biotech market, Abbott Laboratories' (ABT) performance has made notable waves. GLOBALT Investments LLC recently acquired 66,390 shares in ABT and Cim LLC invested $1.87million. Institutional shareholders control a significant 77% of the company. There have been periods where ABT stock underperformed compared to competitors, however, they have also outperformed on strong trading days. Investment activity is vibrant; Baird Financial Group Inc. purchased 297,789 shares, whereas Petredis Investment Advisors LLC sold 820 shares. The company recently announced a quarterly dividend of $0.55, attracting further investor attention. Notwithstanding fluctuations, investment in ABT five years ago would have yielded a 46% gain. The FDA recently approved two glucose monitoring systems by the company, indicating progress in product development. A bearish sign was indicated despite a 'solid' quarterly report. ABT's Q1 revenue increased due to strong medical devices sales, and subsequently boosted annual guidance. Insider actions highlight Executive Vice President Lisa Earnhardt selling 22,852 shares of ABT.
Abbott Laboratories ABT News Analytics from Wed, 03 Jan 2024 08:00:00 GMT to Sun, 16 Jun 2024 17:34:02 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
